comprehensive -WSS

comprehensive

author：hotspot 2025-10-02 00:27:30 - browse：8

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Heat waves linked to early deliveries, preterm births in new study

focus

hotspot

WSS

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Heat waves linked to early deliveries, preterm births in new study

Addiction doctors spar with methadone clinics over legislation

For Medicare Advantage, Democrats want stronger protections around AI

Akili, maker of video game for ADHD, to be acquired for 34 million

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Average age of first period drops to 11.9 years, study shows

The cancer drug shortage isn’t new — and neither are the solutions

'Revelatory' study finds a smoking impact that remains after quitting

United colonoscopy coverage change 'may cost lives,' doctors say

Addiction doctors spar with methadone clinics over legislation

Moonlake's readout produced a cash windfall. Risks remain

Medicare Advantage proposed rates disappoint insurers

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

leisure time

Gilead might be held responsible for not developing a drug

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Key House Republican on health care plans exit from Congress

Why did Pfizer dish out millions for a Super Bowl ad?

Robert F. Kennedy is pitching centrism on health, even on abortion

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

focus

focus

hotspot

Wikipedia